Diabetes drugs: Historical regulatory decisions over the past 17 years

Pharmaceutical Medicine

Volumn 25, Issue 5, 2011, Pages 285-291

  Merante, Domenico ^a   Ceriello, Antonio ^b  

^a DAIICHI SANKYO CO   (Japan)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Acarbose; Benefit risk assessment; Colesevelam; Dapagliflozin; Diabetes mellitus; European Medicines Agency; Exenatide; Food and Drug Administration; Glibenclamidemetformin; Glimepiride; Glipizidemetformin; Glucagon; Insulin; Insulin aspart; Insulin aspartinsulin protamine aspart; Insulin detemir; Insulin glargine; Insulin glulisine; Insulin lispro; Labelling; Linagliptin; Liraglutide; Metformin; Metforminpioglitazone; Miglitol; Nateglinide; Pharmaceutical industry; Pioglitazone; Pioglitazoneglimepiride; Pramlintide; Product approvals; Repaglinide; Rosiglitazone; Rosiglitazoneglimepiride; Rosiglitazonemetformin, use; Saxagliptin; Saxagliptinmetformin; Sitagliptin; Sitagliptinmetformin; Thiazolidinediones; Troglitazone; Vildagliptin; Vildagliptinmetformin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; COLESEVELAM; DIASTOBOL; EXENDIN 4; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIMEPIRIDE PLUS PIOGLITAZONE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLIPIZIDE PLUS METFORMIN; GLITAZONE DERIVATIVE; GLUCAGON; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; METFORMIN PLUS SAXAGLIPTIN; METFORMIN PLUS SITAGLIPTIN; METFORMIN PLUS VILDAGLIPTIN; MIGLIBAY; MIGLITOL; MIGLITOL BAYER; NATEGLINIDE; NOVOMIX 50; NOVOMIX 70; PHENFORMIN; PIOGLITAZONE; PLUMAROL; PRAMLINTIDE; RECOMBINANT GLUCAGON; RECOMBINANT HUMAN INSULIN; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

BLADDER CANCER; CARDIOVASCULAR RISK; COMMON COLD; DIABETES MELLITUS; DIZZINESS; DRUG APPROVAL; DRUG LABELING; DRUG MARKETING; DRUG RECALL; DRUG SAFETY; EUROPEAN MEDICINES AGENCY; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEALTH CARE ORGANIZATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; UNITED STATES;

EID: 80052899239     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.2165/11595300-000000000-00000     Document Type: Review

References (31)

1. CenterWatch.FDAapproved drugs for endocrinology [online]. Available from URL: http://www.centerwatch.com/drug-information/fda-approvals/drugareas. aspx?AreaID=4 [Accessed 2011 Jun 15]
2. Nathan DM. Finding new treatments for diabetes: how many, how fast ... how good. N Engl J Med 2007; 356 (5): 437-43
3. Diabesity Drugs. Your online resource for obesity and non-insulin type 2 diabetes drugs [online]. Available from URL: http://diabesitydrugs.com/ termsofuse.htm [Accessed 2011 Jun 15]
4. European Medicine Agency. EMA latest news index [online]. Available from URL: ttp://www.ema.europa.eu/ema/index.jsp?curl=/pages/home/Home-Page. jsp&jsenabled=true- [Accessed 2011 Jun 15]
5. US Food and Drug Administration [online]. Available from URL: http://www.fda.gov/ [Accessed 2011 Jun 15]
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).Lancet 1998; 352: 854-65
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl JMed 2007; 356: 2467-71
8. Guidance for Industry. Diabetes mellitus: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm071627.pdf [Accessed 2011 Mar 10]
9. The European Agency for the Evaluation of Medicinal Products. Note for guidance for clinical investigation of medicinal products in the treatment of diabetes mellitus. 2002 May 30: CPMP/EWP/1080/00 [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003262.pdf [Accessed 2011 Jun 15]
10. Committee for Medicinal Products for HumanUse. Concept paper on the need for revision of the note for guidance on clinical investigation on medicinal products in the treatment of diabetes mellitus [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003182.pdf [Accessed 2011 Jun 15]
11. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus: draft. 2010 Jan 20 - CPMP/ EWP/1080/00 Rev. 1 [online]. Available from URL: http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2010/02/WC500073570. pdf [Accessed 2011 Jun 15]
12. Kolata GB. The phenformin ban: is the drug an imminent hazard? Science 1979; 203: 1094-6
13. KumarA, NugentK,Kalakunja A, et al. Severe acidosis in a patient with type 2 diabetes mellitus, hypertension, and renal failure. Chest 2003; 123: 1726-9 (Pubitemid 36549795)
14. Mariano F, Benzi L, Cecchetti P, et al. Efficacy of continuous venous venous hemofiltration (CVVH) in treatment of severe phenformin-induced lactic acidosis. Nephrol Dial Transplant 1998; 13: 1012-5 (Pubitemid 28161786)
15. Bailey CJ, Campbell IA, Chan JCN, et al, editors. Metformin: the gold standard: a scientific handbook. Chichester: J Wiley & Sons, Ltd, 2007
16. Misbin RI. Lessons from the Avandia controversy. Diabetes Care 2007 Dec; 30 (12): 3141-4
17. WHO Drug Information. Regulatory matters - Vol. 13, No 2, 1999 [online]. Available from URL: http://whqlibdoc.who.int/druginfo/DRUG-INFO- 13-2-1999-p91-95.pdf [Accessed 2011 Jul 25]
18. ICH. History and future of ICH [online]. Available from URL: http://www.ich.org/about/history.html [Accessed 2011 Jun 15]
19. US Food and Drug Administration. Information for healthcare professionals rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl) [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/Post marketDrugSafetyInformationforPatientsandProviders/ucm143406.htm#2007-5 [Accessed 2011 Jun 16]
20. Dormandy JA, Charbonnel B, Eckland DJ, et al., PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro-Vascular Events): a randomised controlled trial. Lancet 2005; 366 (9493): 1279-89 (Pubitemid 41416583)
21. Woodcock J, Sharfstein JM, Hamburg M. Regulatory action on rosiglitazone by theU.S. Food and Drug Administration.NEngl JMed 2010; 363: 1489-91
22. First World.Germany follows France in suspension of Takeda's Actos [online]. Available from URL: http://www.firstwordplus.com/Fws.do?articleid= 7529D72160AD4A14A53847F9AE3D9789 [Accessed 2011 Jun 14]
23. European Medicines Agency. EMA recommends new contra-indications and warnings for pioglitazone to reduce small increase risk of bladder cancer. Press release 2011 Jul 21 [online]. Available from URL: http://www.ema.europa.eu/ema/ index.jsp?curl=pages/news-and-events/news/2011/07/news-detail-001311. jsp&murl=menus/news-and-events/news-and-events.jsp&mid= WC0b01ac058004d5c1 [Accessed 2011 Jul 25]
24. European Medicines Agency. EMA updates on ongoing benefit/risk review of pioglitazone-containing medicines. Press release 2011 Jun 23 [online]. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/ news/2011/06/news-detail-001284.jsp&mid=WC0b01ac058004d5c1&murl=menus/ news-and-events/news-and-events.jsp&jsenabled=true [Accessed 2011 Jun 29]
25. US Food and Drug Administration. FDA actos (pioglitazone): ongoing safety review. Potential increased risk of bladder cancer [online]. Available from URL: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlerts forHumanMedicalProducts/ucm226257.htm [Accessed 2011 Jul 25]
26. Takeda Pharmaceutical Company Limited. Takeda receives new information on alogliptin (SYR-322) NDA. Press release 2009 Mar 6 [online]. Available from URL: http://www.takeda.com/press/article-32750.html [Accessed 2011 Jun 16]
27. Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003; 46 (13): 2774-89 (Pubitemid 36702545)
28. Hughes B. 2007 FDA drug approvals: a year of flux. Nature Reviews Drug Discovery 2008 Feb; 7: 107-9
29. US Food and Drug Administration. FDA approves new treatment for type 2 diabetes [online]. Available from URL: http://www.fda.gov/newsevents/ newsroom/pressannouncements/ucm198638.htm [Accessed 2011 Jun 15]
30. ADA & EASD 2009 guidelines for screening, diagnosing, and treating diabetes [online]. Available from URL: http://www.diabetesclinic.ca/en/prof/ada- easd-guidelines-2009.doc [Accessed 2011 Jun 15]
31. Nathan DM, Buse JB, Davidson MB, et al., American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009 Jan; 32 (1): 193-203